I'm just wondering if some of those funds raised in past months also have been spent on the material supply, and subsequent license of the booster agent (most likely Poly ICLC) referenced in the previous Q?
The Company has also completed negotiations and entered into a contract with a company that has an immune booster agent that may have the potential to further increase the potency of DCVax products. The contract provides for material supply and in vitro testing of the booster agent with DCVax products. If the in vitro testing is successful, the parties plan to enter into a license of the booster agent to NWBio. The parties jointly designed the program of experiments, and the experiments were carried out and completed by the Flaskworks team. The parties are now evaluating the results and developing plans for further experiments. page 28 https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm
Being that advent is owned by a private entity LP as we all know you cannot funnel money from a public company into a private one,that is called fraud . Don't even know how you would show that on the books, " hey I am just giving away shareholders money to myself "
Increasing capacity means new areas under development or finished fitting out of current suites at Advent right? New areas would have been fitted out with fully digitized Flaskworks processors as well as any additional processors used for manufacturing. The recent inspection of the facility and certification of the finished 1b buildout area likely had Flaskworks processors installed for comparability studies and possibly also had the choice of manufacturing equipment for Direct installed and approved as well to have a basic starting point for any clinical trial. This would have entailed a significant amount of very expensive finishing work before any inspection. Is this what you are suggesting has been done? Best wishes.